KR20080070951A - 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 - Google Patents
아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 Download PDFInfo
- Publication number
- KR20080070951A KR20080070951A KR1020070008896A KR20070008896A KR20080070951A KR 20080070951 A KR20080070951 A KR 20080070951A KR 1020070008896 A KR1020070008896 A KR 1020070008896A KR 20070008896 A KR20070008896 A KR 20070008896A KR 20080070951 A KR20080070951 A KR 20080070951A
- Authority
- KR
- South Korea
- Prior art keywords
- strontium
- atorvastatin
- hydrate
- salt
- formula
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
Claims (14)
- 제 1 항에 있어서,결정형인 것을 특징으로 하는, 아토바스타틴 스트론튬염 또는 이의 수화물.
- 제 2 항에 있어서,X-선 분말 회절분광도에서 10% 이상의 상대 강도 (I/Io : I는 각 피크의 강도; Io는 가장 큰 피크의 강도)를 갖는 피크가 4.0, 4.8, 5.9, 6.5, 7.3, 7.8, 8.8, 9.5, 9.8, 10.2, 11.6, 14.7, 17.5, 18.9, 19.5, 19.8, 20.2, 21.3, 22.7, 23.1, 24.3, 25.6 및 26.3의 회절각(2θ±0.2)에서 나타나는 것을 특징으로 하는, 아토바스타틴 스트론튬염 또는 이의 수화물.
- 제 2 항에 있어서,X-선 분말 회절분광도에서 10% 이상의 상대 강도 (I/Io : I는 각 피크의 강도; Io는 가장 큰 피크의 강도)를 갖는 피크가 4.0, 5.0, 6.4, 8.0, 10.0, 10.3, 12.7, 13.0, 16.6, 18.6, 19.1, 20.0, 21.8 및 22.2의 회절각(2θ±0.2)에서 나타나는 것을 특징으로 하는, 아토바스타틴 스트론튬염 또는 이의 수화물.
- 제 2 항에 있어서,X-선 분말 회절분광도에서 10% 이상의 상대 강도 (I/Io : I는 각 피크의 강도; Io는 가장 큰 피크의 강도)를 갖는 피크가 3.8, 5.2, 6.2, 7.9, 10.7, 19.7 및 24.0의 회절각(2θ±0.2)에서 나타나는 것을 특징으로 하는, 아토바스타틴 스트론튬염 또는 이의 수화물.
- 제 2 항에 있어서,X-선 분말 회절분광도에서 10% 이상의 상대 강도 (I/Io : I는 각 피크의 강도; Io는 가장 큰 피크의 강도)를 갖는 피크가 3.8, 5.2, 5.8, 6.2, 7.6, 8.1, 9.2, 10.3, 11.9, 15.5, 18.1, 19.8, 20.7, 21.1, 22.1, 23.2, 24.3 및 26.3의 회절각(2θ±0.2)에서 나타나는 것을 특징으로 하는, 아토바스타틴 스트론튬염 또는 이의 수화물.
- 제 1 항에 있어서,X-선 분말 회절분광도에서 10% 이상의 상대 강도 (I/Io : I는 각 피크의 강도; Io는 가장 큰 피크의 강도)를 갖는 피크가 나타나지 않는 무정형인 것을 특징으로 하는, 아토바스타틴 스트론튬염 또는 이의 수화물.
- 제 9 항에 있어서,반응성 스트론튬염이 염화스트론튬, 브롬화스트론튬, 황산스트론튬, 질산스트론튬, 과염소산스트론튬, 초산스트론튬, 탄산스트론튬, 옥살산스트론튬 또는 이들의 혼합물인 것을 특징으로 하는 방법.
- 유효성분으로 제1항의 아토바스타틴 스트론튬염 또는 이의 수화물을 포함하는, 고지혈증 및 고콜레스테롤혈증의 치료 및 예방용 약학 조성물.
- 제 11 항에 있어서,경구투여 제제로 제형화되는 것을 특징으로 하는 조성물.
- 제 12 항에 있어서,상기 경구투여 제제에서 아토바스타틴 스트론튬염 또는 이의 수화물이 조성물의 총량을 기준으로 0.1 내지 95 중량%의 양으로 포함되는 것을 특징으로 하는 조성물.
- 제 13 항에 있어서,상기 경구투여 제제에서 아토바스타틴 스트론튬염 또는 이의 수화물이 조성물의 총 중량을 기준으로 1 내지 70 중량%의 양으로 포함되는 것을 특징으로 하는 조성물.
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070008896A KR100878140B1 (ko) | 2007-01-29 | 2007-01-29 | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 |
AU2008211906A AU2008211906B2 (en) | 2007-01-29 | 2008-01-21 | Atorvastatin strontium salt and pharmaceutical composition comprising same |
NZ579339A NZ579339A (en) | 2007-01-29 | 2008-01-21 | Atorvastatin strontium salt and pharmaceutical composition comprising the same |
BRPI0808369-0A BRPI0808369A2 (pt) | 2007-01-29 | 2008-01-21 | Sal de estrôncio de atorvastatina e composição farmacêutica compreendendo o mesmo |
US12/524,807 US20100120888A1 (en) | 2007-01-29 | 2008-01-21 | Atorvastatin strontium salt and pharmaceutical composition comprising same |
CL200800170A CL2008000170A1 (es) | 2007-01-29 | 2008-01-21 | Sal estroncica de atorvastatina, o sus hidratos o polimorfos; metodo de preparacion; composicion farmaceutica, util para la prevencion o tratamiento de hiperlipidemia e hipercolesterolemia. |
EP08704884A EP2121596A4 (en) | 2007-01-29 | 2008-01-21 | ATORVASTATIN STRONTIUM SALT AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF |
CA002675996A CA2675996A1 (en) | 2007-01-29 | 2008-01-21 | Atorvastatin strontium salt and pharmaceutical composition comprising same |
PCT/KR2008/000357 WO2008093951A1 (en) | 2007-01-29 | 2008-01-21 | Atorvastatin strontium salt and pharmaceutical composition comprising same |
JP2009547168A JP2010516756A (ja) | 2007-01-29 | 2008-01-21 | アトルバスタチンのストロンチウム塩、及びこれを含む医薬組成物 |
MX2009007922A MX2009007922A (es) | 2007-01-29 | 2008-01-21 | Sal de estroncio de atorvastatina y composicion farmaceutica que la contiene. |
CNA2008800034354A CN101600688A (zh) | 2007-01-29 | 2008-01-21 | 阿托伐他汀锶盐以及包含该物质的药物组合物 |
PE2008000205A PE20081722A1 (es) | 2007-01-29 | 2008-01-28 | Sal estroncio de atorvastatina y composicion farmaceutica que la incluye |
TW097103064A TW200844093A (en) | 2007-01-29 | 2008-01-28 | Atorvastatin strontium salt and pharmaceutical composition comprising same |
ARP080100349A AR065070A1 (es) | 2007-01-29 | 2008-01-29 | Sal de estronico de atorvastatina y una composicion farmaceutica que la comprende |
IL200069A IL200069A0 (en) | 2007-01-29 | 2009-07-26 | Atorvastatin strontium salts, pharmaceutical composition comprising the same and methods of producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070008896A KR100878140B1 (ko) | 2007-01-29 | 2007-01-29 | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080070951A true KR20080070951A (ko) | 2008-08-01 |
KR100878140B1 KR100878140B1 (ko) | 2009-01-12 |
Family
ID=39674220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070008896A KR100878140B1 (ko) | 2007-01-29 | 2007-01-29 | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100120888A1 (ko) |
EP (1) | EP2121596A4 (ko) |
JP (1) | JP2010516756A (ko) |
KR (1) | KR100878140B1 (ko) |
CN (1) | CN101600688A (ko) |
AR (1) | AR065070A1 (ko) |
AU (1) | AU2008211906B2 (ko) |
BR (1) | BRPI0808369A2 (ko) |
CA (1) | CA2675996A1 (ko) |
CL (1) | CL2008000170A1 (ko) |
IL (1) | IL200069A0 (ko) |
MX (1) | MX2009007922A (ko) |
NZ (1) | NZ579339A (ko) |
PE (1) | PE20081722A1 (ko) |
TW (1) | TW200844093A (ko) |
WO (1) | WO2008093951A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10252993B2 (en) | 2010-07-28 | 2019-04-09 | Kyongbo Pharm | Crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102976996B (zh) * | 2009-05-27 | 2015-08-19 | 峡江和美药业有限公司 | 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用 |
WO2013107236A1 (zh) * | 2012-01-20 | 2013-07-25 | 连云港金康和信药业有限公司 | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 |
CN102935076A (zh) * | 2012-11-29 | 2013-02-20 | 康普药业股份有限公司 | 一种含阿托伐他汀钠的胶囊及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
DE69616808T2 (de) * | 1995-07-17 | 2002-05-29 | Warner Lambert Co | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin) |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
CN1524073A (zh) | 2001-06-29 | 2004-08-25 | ����-�����ع�˾ | ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基)羰基-1H-吡咯-1-庚酸钙盐(2∶1)(阿托伐他汀) |
AU2005240257B2 (en) * | 2004-05-06 | 2011-11-24 | Osteologix A/S | High yield and rapid syntheses methods for producing metallo-organic salts |
JP2008502609A (ja) * | 2004-06-17 | 2008-01-31 | オステオロジックス エイ/エス | リウマチおよび関節性疾患の治療改善方法 |
-
2007
- 2007-01-29 KR KR1020070008896A patent/KR100878140B1/ko active IP Right Grant
-
2008
- 2008-01-21 EP EP08704884A patent/EP2121596A4/en not_active Withdrawn
- 2008-01-21 AU AU2008211906A patent/AU2008211906B2/en not_active Expired - Fee Related
- 2008-01-21 NZ NZ579339A patent/NZ579339A/en unknown
- 2008-01-21 JP JP2009547168A patent/JP2010516756A/ja not_active Withdrawn
- 2008-01-21 CN CNA2008800034354A patent/CN101600688A/zh active Pending
- 2008-01-21 WO PCT/KR2008/000357 patent/WO2008093951A1/en active Application Filing
- 2008-01-21 US US12/524,807 patent/US20100120888A1/en not_active Abandoned
- 2008-01-21 MX MX2009007922A patent/MX2009007922A/es not_active Application Discontinuation
- 2008-01-21 CA CA002675996A patent/CA2675996A1/en not_active Abandoned
- 2008-01-21 CL CL200800170A patent/CL2008000170A1/es unknown
- 2008-01-21 BR BRPI0808369-0A patent/BRPI0808369A2/pt not_active IP Right Cessation
- 2008-01-28 TW TW097103064A patent/TW200844093A/zh unknown
- 2008-01-28 PE PE2008000205A patent/PE20081722A1/es not_active Application Discontinuation
- 2008-01-29 AR ARP080100349A patent/AR065070A1/es not_active Application Discontinuation
-
2009
- 2009-07-26 IL IL200069A patent/IL200069A0/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10252993B2 (en) | 2010-07-28 | 2019-04-09 | Kyongbo Pharm | Crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same |
Also Published As
Publication number | Publication date |
---|---|
US20100120888A1 (en) | 2010-05-13 |
AR065070A1 (es) | 2009-05-13 |
AU2008211906A1 (en) | 2008-08-07 |
JP2010516756A (ja) | 2010-05-20 |
TW200844093A (en) | 2008-11-16 |
KR100878140B1 (ko) | 2009-01-12 |
MX2009007922A (es) | 2009-08-07 |
BRPI0808369A2 (pt) | 2014-08-19 |
PE20081722A1 (es) | 2009-01-22 |
NZ579339A (en) | 2011-03-31 |
AU2008211906B2 (en) | 2010-11-18 |
EP2121596A1 (en) | 2009-11-25 |
CL2008000170A1 (es) | 2008-05-23 |
EP2121596A4 (en) | 2010-03-17 |
CN101600688A (zh) | 2009-12-09 |
CA2675996A1 (en) | 2008-08-07 |
WO2008093951A1 (en) | 2008-08-07 |
IL200069A0 (en) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3965155B2 (ja) | 結晶型[R−(R*,R*)]−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチルエチル)−3−フェニル−4−[(フェニルアミノ)カルボニル]−1H−ピロール−1−ヘプタン酸カルシウム塩(2:1)(アトロバスタチン) | |
KR100704213B1 (ko) | 아토르바스타틴 헤미-칼슘 vii형 | |
HU223598B1 (hu) | (III) formájú kristályos [R-(R*,R*)]-2-(4-fluor-fenil)-béta,delta-dihidroxi-5-(1-metil-etil)-3-fenil-4-[(fenil-amino)-karbonil]-1H-pirrol-1-heptánkarbonsav- hemikalciumsó-hidrát (atorvastatin-hidrát) és a vegyületet tartalmazó gyógyászati készítmény | |
KR20020063190A (ko) | 아토르바스타틴 칼슘의 다형태 | |
RU2304139C2 (ru) | Кристаллические формы vi и vii кальциевой соли аторвастатина | |
EA000474B1 (ru) | Кристаллическая кислая кальциевая соль [r-(r*, r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1н-пиррол-1-гептановой кислоты (аторвастатин) | |
CN112119078A (zh) | Tlr7/tlr8抑制剂的晶型 | |
KR100878140B1 (ko) | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 | |
KR20130014643A (ko) | 퀴놀린 화합물의 결정형 및 그의 제조 방법 | |
EP1490333B1 (en) | New atorvastatin salts and pharmaceutical compositions containing them | |
US20080269315A1 (en) | Crystalline form | |
PT1732886E (pt) | Polimorfos de éster de tert-butilo de atorvastatina e utilização como intermediários para a preparação de atorvastatina | |
TW200900392A (en) | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same | |
US20100260851A1 (en) | Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium | |
TWI705065B (zh) | 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途 | |
KR101012917B1 (ko) | 피롤 헵탄산 화합물의 신규한 결정형 | |
RU2315755C2 (ru) | Кристаллические формы [r-(r*,r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1н-пиррол-1-гептановой кислоты | |
WO2006048894A1 (en) | Novel crystalline forms of atorvastatin calcium and processes for preparing them. | |
JP2008500327A (ja) | アトルバスタチンの塩形態 | |
EP1786771B1 (en) | Novel polymorphs of the potassium salt of atorvastatin | |
KR101723783B1 (ko) | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 | |
WO2013095307A1 (en) | New crystal salts of zofenopril, process for obtaining them and their use in therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120313 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131231 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141215 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20161216 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180104 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20181218 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20191226 Year of fee payment: 12 |